[go: up one dir, main page]

NO20091598L - P-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazol(4,5-d)pyrimidin-2-on og fremgangsmater for fremstilling derav - Google Patents

P-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazol(4,5-d)pyrimidin-2-on og fremgangsmater for fremstilling derav

Info

Publication number
NO20091598L
NO20091598L NO20091598A NO20091598A NO20091598L NO 20091598 L NO20091598 L NO 20091598L NO 20091598 A NO20091598 A NO 20091598A NO 20091598 A NO20091598 A NO 20091598A NO 20091598 L NO20091598 L NO 20091598L
Authority
NO
Norway
Prior art keywords
ribofuranosyl
deoxy
acetyl
amino
preparation
Prior art date
Application number
NO20091598A
Other languages
English (en)
Inventor
David J Kucera
Tingmin Wang
Gregory J Haley
Erik J Rueden
Fritz Blatter
Martin Viertelhaus
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of NO20091598L publication Critical patent/NO20091598L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det beskrives p-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d]pyrimidin-2-on og dets anvendelse til behandling av slike tilstander som virusinfeksjoner, tumorer og cancer. Videre beskrives en fremgangsmåte for fremstilling av p-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-?-D-ribofuranosyl)-3H-tiazolo[4,5-d]pyrimidin-2-on og fremgangsmåter for fremstilling av furanoseforbindelser som er anvendelige mellomprodukter ved fremstillingen av farmasøytiske forbindelser som p-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-?-D-ribofuranosyl)-3H-tiazolo[4,5-d]pyrimidin-2-on og lignende.
NO20091598A 2006-10-17 2009-04-22 P-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazol(4,5-d)pyrimidin-2-on og fremgangsmater for fremstilling derav NO20091598L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85200206P 2006-10-17 2006-10-17
US89940507P 2007-02-05 2007-02-05
US95359707P 2007-08-02 2007-08-02
PCT/US2007/081526 WO2008140549A1 (en) 2006-10-17 2007-10-16 P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-β-D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D] PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION

Publications (1)

Publication Number Publication Date
NO20091598L true NO20091598L (no) 2009-07-10

Family

ID=39472747

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091598A NO20091598L (no) 2006-10-17 2009-04-22 P-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazol(4,5-d)pyrimidin-2-on og fremgangsmater for fremstilling derav

Country Status (24)

Country Link
US (2) US7928085B2 (no)
EP (1) EP2076132B1 (no)
JP (2) JP5279715B2 (no)
KR (2) KR101515077B1 (no)
AR (1) AR063484A1 (no)
AU (1) AU2007353381B2 (no)
BR (1) BRPI0717741A2 (no)
CA (2) CA2666537C (no)
CY (1) CY1113368T1 (no)
DK (1) DK2076132T3 (no)
DO (1) DOP2007000131A (no)
EA (1) EA017005B1 (no)
ES (1) ES2390930T3 (no)
IL (2) IL198180A (no)
MX (1) MX2009004028A (no)
MY (1) MY150408A (no)
NO (1) NO20091598L (no)
NZ (1) NZ576408A (no)
PE (1) PE20081105A1 (no)
PL (1) PL2076132T3 (no)
PT (1) PT2076132E (no)
TW (1) TWI415854B (no)
UY (1) UY30650A1 (no)
WO (1) WO2008140549A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709448B2 (en) 2006-06-22 2010-05-04 Anadys Pharmaceuticals, Inc. Prodrugs of 5-amino-3-(3′-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
US20110166092A1 (en) 2007-08-20 2011-07-07 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
MA41134B1 (fr) 2014-12-08 2021-03-31 Hoffmann La Roche Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
RU2718917C2 (ru) 2015-03-16 2020-04-15 Ф. Хоффманн-Ля Рош Аг Комбинированное лечение агонистом толл-подобного рецептора (tlr7) и ингибитором сборки капсида вируса гепатита в
EP3294745B1 (en) 2015-05-08 2020-01-01 H. Hoffnabb-La Roche Ag Novel oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection
EP4001283A1 (en) 2015-05-12 2022-05-25 F. Hoffmann-La Roche AG Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
EP3317289B1 (en) 2015-06-30 2021-10-27 F. Hoffmann-La Roche AG Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
US11142534B2 (en) * 2017-01-06 2021-10-12 Hoffmann-La Roche Inc. Process for the preparation of 3-substituted 5-amino-6H-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
CN110007010A (zh) * 2018-01-05 2019-07-12 大鹏药品工业株式会社 源自曲氟尿苷的类似物质的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07224081A (ja) * 1994-02-10 1995-08-22 Kobayashi Koryo Kk デオキシリボフラノシルハライド誘導体の製造方法
US5532374A (en) * 1995-06-06 1996-07-02 Hitachi Chemical Company, Ltd. Method of preparation of bis-quinolines
JP4067226B2 (ja) * 1999-04-01 2008-03-26 三井化学株式会社 １―ハロゲノ−２−デオキシリボフラノース誘導体の製造方法
JP2000327693A (ja) * 1999-05-21 2000-11-28 Mitsui Chemicals Inc ２’−デオキシ−β−シチジン誘導体の製造方法
US6649761B2 (en) 2001-05-30 2003-11-18 Merck & Co., Inc. Process for preparing piperazinepentaneamide HIV protease inhibitors
IL162137A0 (en) * 2001-11-27 2005-11-20 Anadys Pharmaceuticals Inc D-ribofuranosylthiazolo -3-Ä4,5-dÜpyridimine nucl eosides and uses thereof
EP1575953A1 (en) * 2002-12-09 2005-09-21 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
ES2342069T4 (es) * 2003-09-05 2011-01-26 Anadys Pharmaceuticals, Inc. Ligandos de tlr7 para el tratamiento de la hepatitis c.
CN1964985A (zh) * 2004-06-07 2007-05-16 阿纳迪斯药物公司 3－β－D－呋喃核糖基噻唑并[4,5－d]嘧啶核苷类及其应用
EP1824482B1 (en) * 2004-12-17 2014-02-12 Anadys Pharmaceuticals, Inc. 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
US7501526B2 (en) * 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
US7709448B2 (en) * 2006-06-22 2010-05-04 Anadys Pharmaceuticals, Inc. Prodrugs of 5-amino-3-(3′-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
CN101595117B (zh) * 2006-12-08 2014-01-22 株式会社Api 呋喃糖衍生物的制造方法

Also Published As

Publication number Publication date
EA200970387A1 (ru) 2009-10-30
KR101486444B1 (ko) 2015-01-26
CA2666537A1 (en) 2008-11-20
TWI415854B (zh) 2013-11-21
JP5703334B2 (ja) 2015-04-15
EP2076132A4 (en) 2011-05-04
WO2008140549A1 (en) 2008-11-20
CA2666537C (en) 2015-12-08
IL198180A0 (en) 2009-12-24
IL223126A0 (en) 2012-12-31
HK1132429A1 (en) 2010-02-26
JP5279715B2 (ja) 2013-09-04
PT2076132E (pt) 2012-10-03
AU2007353381A1 (en) 2008-11-20
IL198180A (en) 2015-06-30
KR20090074237A (ko) 2009-07-06
KR20140119203A (ko) 2014-10-08
IL223126A (en) 2016-08-31
EP2076132B1 (en) 2012-07-11
CY1113368T1 (el) 2016-06-22
BRPI0717741A2 (pt) 2014-04-08
AU2007353381B2 (en) 2013-07-04
US8193342B2 (en) 2012-06-05
UY30650A1 (es) 2008-05-31
TW200833699A (en) 2008-08-16
JP2013166782A (ja) 2013-08-29
AR063484A1 (es) 2009-01-28
DOP2007000131A (es) 2008-09-15
MY150408A (en) 2014-01-15
JP2010506947A (ja) 2010-03-04
KR101515077B1 (ko) 2015-04-24
NZ576408A (en) 2012-04-27
ES2390930T3 (es) 2012-11-19
EP2076132A1 (en) 2009-07-08
US20090197826A1 (en) 2009-08-06
EA017005B1 (ru) 2012-09-28
CA2898225A1 (en) 2008-11-20
US20110172447A1 (en) 2011-07-14
PE20081105A1 (es) 2008-08-15
DK2076132T3 (da) 2012-09-10
MX2009004028A (es) 2009-05-11
US7928085B2 (en) 2011-04-19
PL2076132T3 (pl) 2013-01-31

Similar Documents

Publication Publication Date Title
NO20091598L (no) P-toluensulfonsyresalt av 5-amino-3-(2'-O-acetyl-3'-deoksy-beta-D-ribofuranosyl)-3H-tiazol(4,5-d)pyrimidin-2-on og fremgangsmater for fremstilling derav
EP2114925A4 (en) AZETIDINE ANALOGUE AIS NUCLEOSIDASE AND PHOSPHORYLASE HEMMER
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
NZ543467A (en) The severe acute respiratory syndrome coronavirus
WO2007041130A3 (en) Deazapurines useful as inhibitors of janus kinases
BRPI0418351A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
NO20072223L (no) Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
WO2005110994A3 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
CR7043A (es) Derivados de eteres utiles como ganetes inhibidores de las isozimas pde4
NO20070782L (no) Tetrapeptidanaloger.
UA99924C2 (en) Benzylbenzol derivatives and using thereof
NO20073367L (no) Makrolider
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
WO2006133099A3 (en) Sirna microbicides for preventing and treating viral diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application